NCT02142608View on ClinicalTrials.gov

A Pilot Trial Using BR55 Ultrasound Contrast Agent in the Assessment of Prostate Cancer

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

19

Participants

Timeline

Start Date

August 31, 2014

Primary Completion Date

July 31, 2015

Study Completion Date

January 31, 2016

Conditions
Prostate Cancer
Interventions
DRUG

BR55

Ultrasound contrast agent

Trial Locations (2)

94305

Translational Molecular Imaging Lab, Stanford

Unknown

Service d'Imagerie Diagnostique et Interventionnelle de l'Adulte, Bordeaux

Sponsors
All Listed Sponsors
lead

Bracco Diagnostics, Inc

INDUSTRY